Invasive mycoses: Management and unmet medical needs

Current Opinion in Infectious Diseases

Volumn 14, Issue 6, 2001, Pages 669-671

  Patterson, Thomas F ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; ITRACONAZOLE; VORICONAZOLE;

ANTIFUNGAL ACTIVITY; ANTIMICROBIAL ACTIVITY; ASPERGILLOSIS; ASPERGILLUS; CANDIDA ALBICANS; EDITORIAL; HEALTH CARE NEED; HIGH RISK PATIENT; HUMAN; MYCOSIS; PRACTICE GUIDELINE;

EID: 0035211506     PISSN: 09517375     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001432-200112000-00001     Document Type: Editorial

References (16)

1. Trends in the postmortem epidemiology of invasive fungal infections at a university hospital
2. Trends in mortality due to invasive mycotic diseases in the United States, 1980-1997
3. Aspergillosis case-fatality rate: Systematic review of the literature
4. Practice guidelines for diseases caused by Aspergillus
5. Invasive aspergillosis: Disease spectrum, treatment practices, and outcomes
6. Need for alternative trial designs and evaluation strategies for therapeutic studies of invasive mycoses
7. Utility of diagnostic criteria for invasive aspergillosis: Consistency of diagnosis in a clinical trial
8. An EORTC international multicenter randomized trial (EORTC number 19923) comparing two dosages of liposomal amphotericin B for treatment of invasive aspergillosis
9. A double-blind randomized controlled trial of amphocil (ABCD) vs amphotericin B (AmB) for treatment of invasive aspergillosis in immunocompromised patients
10. Open, randomised comparison of voriconazole (VRC) and amphotericin B (AmB) followed by other licensed antifungal Therapy (OLAT) for primary therapy of invasive aspergillosis (IA)
11. Emergency-use amphotericin B lipid complex (ABLC) in the treatment of patients with aspergillosis: Historical control comparison with amphotericin B
12. Efficacy of caspofungin as salvage therapy in invasive aspergillosis (IA) as compared to standard therapy in a historical cohort
13. Liposomal amphotericin B compared with amphotericin B deoxycholate in the treatment of documented and suspected neutropenia-associated invasive fungal infections
14. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia
15. Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy. A randomized, controlled trial
16. Voriconazole versus liposomal amphotericin B for empirical antifungal therapy of persistently febrile neutropenic patients: A randomized, international, multicenter trial